PDS Biotechnology Corp Additional Paid in Capital, Common Stock
PDS Biotechnology Corp (PDSB) had Additional Paid in Capital, Common Stock of $19.87 million as of 2018-12-31, per its 10-K filed 2020-03-27.
Discontinued › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2020-03-27
- 2018-12-31: Additional Paid in Capital, Common Stock $19.87M.
- 2016-12-31: Additional Paid in Capital, Common Stock $190.34M.
- 2016-09-30: Additional Paid in Capital, Common Stock $189.06M.
- 2016-06-30: Additional Paid in Capital, Common Stock $187.55M.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2018-12-31 | $19.87M 10-K · filed 2020-03-27 |
| 2016-12-31 | $190.34M 10-K · filed 2017-03-02 |
| 2016-09-30 | $189.06M 10-Q · filed 2016-11-01 |
| 2016-06-30 | $187.55M 10-Q · filed 2016-08-03 |
| 2016-03-31 | $186.14M 10-Q · filed 2016-05-03 |
| 2015-12-31 | $184.72M 10-K · filed 2017-03-02 |
| 2015-09-30 | $3.55M 10-Q · filed 2015-11-06 |
| 2014-12-31 | $1.98M 10-K · filed 2016-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |